ticlopidine has been researched along with Hemorrhagic Disorders in 8 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hemorrhagic Disorders: Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The work of many investigators since adenosine diphosphate (ADP) was recognized as a platelet aggregating agent in 1961 has led to an appreciation of the important part that ADP plays in hemostasis and thrombosis." | 4.82 | Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. ( Mustard, JF; Packham, MA, 2005) |
| "Adenosine diphosphate (ADP) and adenosine triphosphate (ATP) play a crucial role in hemostasis and thrombosis, and their receptors are potential targets for antithrombotic drugs." | 4.82 | The platelet P2 receptors in thrombosis. ( Gachet, C; Hechler, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nizarali, N | 1 |
| Rafique, S | 1 |
| Wolf, Z | 1 |
| Mani, H | 1 |
| Lindhoff-Last, E | 1 |
| Lang, T | 1 |
| Fernandez, JS | 1 |
| Sadaniantz, BT | 1 |
| Sadaniantz, A | 1 |
| Packham, MA | 1 |
| Mustard, JF | 1 |
| Gachet, C | 1 |
| Hechler, B | 1 |
| Potapov, EV | 1 |
| Hetzer, R | 1 |
| Herbert, JM | 1 |
| Bernat, A | 1 |
| Maffrand, JP | 1 |
5 reviews available for ticlopidine and Hemorrhagic Disorders
| Article | Year |
|---|---|
[Significance of platelet function tests].
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelet Disorders; Clopidogrel; Collagen; H | 2010 |
[Current coagulation diagnostics in intensive care medicine].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Cost-Benefit Analysis; Early Diagnosi | 2011 |
Review of antithrombotic agents used for acute coronary syndromes in renal patients.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Fib | 2003 |
Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adenylyl Cyclases; Animals; Calcium; Calcium Signalin | 2005 |
The platelet P2 receptors in thrombosis.
Topics: Adenosine Diphosphate; Animals; Blood Vessels; Clinical Trials as Topic; Clopidogrel; Fibrinolytic A | 2005 |
3 other studies available for ticlopidine and Hemorrhagic Disorders
| Article | Year |
|---|---|
Special Care Dentistry: Part 2. dental management of patients with drug-related acquired bleeding disorders.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Age | 2013 |
Impact of PlA polymorphism of platelet GP IIb/IIIa receptors on clinical course during long-term LVAD support is independent of type of LVAD.
Topics: Anticoagulants; Antigens, Human Platelet; Aspirin; Clopidogrel; Equipment Design; Genetic Predisposi | 2006 |
Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat.
Topics: Animals; Aprotinin; Arteriovenous Shunt, Surgical; Bleeding Time; Clopidogrel; Constriction; Hemorrh | 1993 |